Reimagining Inhaled Anesthesia
Is sevoflurane as good as it gets?
Shane Austin, PhD
Chief Executive Officer, Expanesthetics
Why innovation in inhaled anesthesia stopped decades ago, why it matters now, and how new mechanistic insights are opening the door to the next generation of agents.
Inhaled anesthetics remain essential to modern surgery, yet the discovery of new agents has been stalled for decades. In this session, Dr. Shane Austin, CEO of Expanesthetics, will explain why pursuing new inhaled anesthetics still matters and why it has proven so difficult. A significant discovery around the molecular mechanism of action of the volatile anesthetics offers an efficient path toward identifying new agents. Recent findings from Expanesthetics' pre-clinical research reveal several compounds with blood-pressure sparing effects, suggesting that smart design could shape the next generation of inhaled anesthesia.
